Sapio Sciences Achieves Hébergeur de Données de Santé (HDS) Certification

01/14/25 – Sapio Sciences, the science-awareTM lab informatics platform, today announced its achievement of the Hébergeur de Données de Santé (HDS) certification, a mandatory requirement for organizations hosting personal health data in France. Read more here!

Sapio Sciences Announces Enhanced Capabilities for Chemistry, Immunogenicity, GMP and Molecular Biology

01/14/25 – Sapio Sciences, the science-awareTM lab informatics platform, today announced the launch of Release 24.12, introducing new capabilities for immunogenicity, GMP workflows, chemistry, and molecular biology. These advancements streamline lab operations, enhance accuracy, and support the growing demands of scientific research. Read more here!

Proactive New Business Development: Fill The Pipeline!

01/13/25 – There are several skills that require mastery to be successful in Sales, but none is as important as finding new opportunities. Proactive new business development must happen. Every day. The inability to do this causes more problems for Sales Management than anything else. Stay ahead of the curve with a simple, executable plan to fill the funnel. Read more here!

Guardant Health Shield Platform Selected for Inclusion in National Cancer Institute’s Vanguard Study to Evaluate Emerging Technologies for Multi-Cancer Detection

01/07/25 – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the National Cancer Institute (NCI) has selected the company’s Shield™ multi-cancer detection (MCD) test for use in its Vanguard study, which will address the feasibility of using MCD tests in future clinical trials related to cancer screening. MCD tests are blood tests that can screen for several types of cancers simultaneously. Read more here!

Are Patent Litigation Expenses Relating to ANDA Tax Deductible?

12/12/24 – Generic drugs typically cost less than the replicated brand-name drugs. It is a cost-effective way of making available expensive essential medications to patients who need them. Generic drugs are priced lower because manufacturers of generic drugs do not have to invest in clinical studies and tests that have already been done by the brand-name manufacturer. Read more here!

Phastar Scoops Prestigious 2024 Scrip Award

12/09/24 – Phastar, a global biometrics CRO, has won the Best CRO – Specialist Providers category at the 2024 Scrip Awards, held at Raffles London at the OWO on December 4th. Recognized for its advanced clinical analytics, data visualization, and innovative Recruitment Forecasting app, Phastar’s Clinical Intelligence Portal was pivotal in securing the accolade. As a certified B Corporation®, the company’s commitment to ESG goals, including Net-Zero targets and community initiatives, further solidified its industry leadership. Read more here!

evitria Partners with Sapio Sciences to Streamline Antibody Workflow Management and Reporting

12/03/24 – Sapio Sciences, the science-aware™ lab informatics platform, today announced that evitria, a leader in antibody expression services, has selected Sapio’s Electronic Lab Notebook (ELN) and Sapio Report Builder to enhance its sample tracking, data capture, and reporting capabilities.. Read more here!

Announcing QuickStart, the Key Building Blocks to Launch a Trade Secret Program

11/26/24 – Nov. 21, 2024 — Tangibly, a SaaS platform for trade secret management and advanced patent analysis, is proud to announce the launch of QuickStart™, a guided workflow to launch a trade secret management program. Read more here!

IRBM Group Achieves Gold Rating for Sustainability from EcoVadis

11/25/24 – IRBM, a leading preclinical drug discovery CRO and former Merck & Co. site achieves an EcoVadis Gold Rating, ranking in the top 5% of all companies rated by EcoVadis and the top 2% in the scientific R&D sector. Recognized for excellence in sustainability, labor & human rights, ethics, and sustainable procurement, this milestone underscores IRBM’s commitment to ESG principles. Read more here!

Gladstone President Deepak Srivastava Named 2024 Distinguished Citizen by Commonwealth Club World Affairs

11/19/24 – In addition to serving as president of Gladstone Institutes, Srivastava oversees the Roddenberry Stem Cell Center at Gladstone and runs his own 20-person research lab focused on finding new ways to treat heart disease and repair heart damage. And, based on discoveries from his lab, he also cofounded two biotechnology companies in the San Francisco Bay Area. Read more here!

Sapio Sciences Collaborates with Waters Corporation to Improve Efficiency of Laboratory Operations

11/18/24 – Sapio Sciences, the science-awareTM lab informatics platform, today announced it has entered a co-marketing agreement with Waters Corporation to enhance data integrity, workflow efficiency, and laboratory productivity. Read more here!

How to Establish Value in Life Sciences Sales

11/7/24 – In the current business landscape, establishing the value of your product or service is more crucial than ever. If you can’t communicate how your offering boosts revenue, reduces costs, improves patient recovery time, or delivers better clinical results, it becomes challenging for potential customers to see why they should choose you over your competitors. Read more here!

Family caregivers perform six-figure work for free

11/5/24 – Family caregivers for loved ones with Alzheimer’s and dementia could earn a six-figure salary if paid for their daily services, according to a new study from Salary.com sponsored by Otsuka. Read more here!

Exclusive Educational Opportunity for Members

10/31/24 – You’re invited to the inaugural Scientists for Sustainability? gala where you will enjoy a private tour of aquarium exhibits and learn how plastic waste impacts the ecosystem of our oceans. Learn how to make your facilities more sustainable through best practice sharing by the event’s sponsors and guest speakers. Read more here!

De-Coupling Process Development from Manufacturing

10/29/24 – For decades, the pharmaceutical industry has relied on the traditional CDMO model to handle the complexities of both process development and manufacturing. While this model has been integral to the industry’s growth, it often leaves medicine developers tethered to manufacturing constraints, limiting flexibility, innovation, and control over the process. Read more here!

Sapio Sciences Enhances Bioanalysis LIMS and ELN with Advanced Immunogenicity Capabilities

10/29/24 – Collaboration enables customers to securely and confidently use AI to accelerate drug research and discovery. Read more here!

Biointron Insights: Antibody Industry Report (Q3 2024 Insights, Trends & Analysis)

10/25/24 – This report aims to explore the events and trends of the biopharmaceutical industry in Q3 (July, August, September). Besides PiaSky, Vyloy, Imdelltra, Tribuvia, and ivonescimab, five more novel antibody drugs have been approved this year. Read more here!

10/16/24 – Labcon received the Product Transparency Award at the 2024 My Green Lab Summit, recognizing our commitment to eco-conscious manufacturing. This year, we expanded our ACT Label portfolio to 251 products (753 labels). Read more here!

Sapio Sciences Enhances Bioanalysis LIMS and ELN with Advanced Immunogenicity Capabilities

10/15/24 – Sapio Sciences, the science-aware lab informatics platform, today announced the addition of new immunogenicity bioanalysis features to its industry-leading lab informatics platform. Read more here!

Whitepaper from the University of Waterloo, Canada

10/10/24 – A new whitepaper from the Department of Chemical Engineering at the University of Waterloo, Canada, explores how Expression Systems? proprietary platform delivers greater per-cell productivity and higher volumetric cell densities resulting in significant increases in total volumetric productivity for VLPs and membrane proteins. Read more here!

MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer

10/10/24 – MaxCyte announced the appointment of Ali Soleymannezhad as Chief Commercial Officer, effective as of September 11, 2024. In his new role, Mr. Soleymannezhad will lead MaxCyte?s commercial operations to increase adoption of the ExPERT Platform, provide best-in-class scientific, technical and regulatory support to customers, and expand the Company?s market impact in Cell and Gene Therapy. Read more here!